Trials / Completed
CompletedNCT00569946
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
PHASE 2 STUDY OF AG-013736 AS SECOND-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CANCER
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-013736 | AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID. Number of cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2007-12-12
- Primary completion
- 2010-02-26
- Completion
- 2012-10-30
- First posted
- 2007-12-10
- Last updated
- 2019-06-05
- Results posted
- 2012-03-27
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00569946. Inclusion in this directory is not an endorsement.